NORD is encouraged by efforts to strengthen and clarify regulatory tools that advance rare disease treatments. For conditions with extremely small patient populations, where traditional clinical trials are difficult to conduct, regulatory flexibility is essential. This draft guidance works within FDA’s existing authorities to support innovation for those with specific genetic conditions, where there are frequently significant unmet needs.
Our shared goal is a science-driven, predictable regulatory system that addresses the unique challenges of orphan drug development. At a time when the rare disease community is facing increased uncertainty due to a number of unexpected decisions on product applications, clarity and consistency in regulatory decision-making are especially important. Patients, families, researchers, and investors are counting on a system that delivers both rigor and reliability.
For families facing a rare disease, regulatory policy isn’t abstract. It is life-defining. It can mean the difference between watching a disease progress with no options and finally having a treatment that improves quality of life and restores hope. The Plausible Mechanism Framework offers promise, and its impact will depend on consistent, transparent implementation that drug developers and patients can trust.
NORD remains committed to working collaboratively with HHS and the FDA to advance safe, effective, and accessible treatments for people living with rare diseases.
